Bayer Corporation

Delinia, Inc.

Atyr Pharma, Inc.

Bayer Pharmaceuticals Corporation

Pangu Biopharma Limited

Aerovance, Inc.

Molecular Therapeutics, Inc.

Other

Kyverna Therapeutics, Inc.

Jeffrey M Greve

Alan McClelland

Armen B Shanafelt

Gary Davis

John D Mendlein

Robert Gundel

Kyle P Chiang

Wing-Sze Lo

Clark Qun Pan

Ying Buechler

Chi-Fang Wu

Ching-Fun Lau

Gary J Jesmok

Steve Roczniak

Malinda Longphre

Niranjana Aditi Nagarajan

Stephanie Yung

Adrian Tomkinson

Gayle D Wetzel

Steven Roczniak

John Cho

Teresa Mo-Fun Wong

Kenneth Lembach

Elisabeth Gardiner

Melissa Ashlock

Jungmin Kim

Kristi Helen Piehl

Ryan Andrew Adams

David C Boisvert

Kathy Delaria

John Lee

Lih-Yun Hsu

Elise Burmeister-Getz

Ashley Mahne

Ching Fun Lau

This invention provides for a fusion protein between an IL2&#x3b1;&#x3b2;&#x3b3; Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2&#x3b1;&#x3b2;&#x3b3; form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.

Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases

This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and one or more transcription factors are provided herein. Methods and materials for treating a mammal having an autoimmune disease comprising administering to a mammal having an autoimmune disease an effective amount of a T cell are also provided herein.

Method for treating disease using FOXP3+CD4+ T cells

This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an IL-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles. The disclosure also provides methods for treating autoimmune disease comprising administering a therapeutically-effective amount of a fusion protein comprising an IL-2 variant protein.

IL-2 variants for the treatment of psoriasis

This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.

Multivalent regulatory T cell modulators

Nucleic acid encoding human IL-2 variant

The invention described herein is a novel IL-2 protein with selective agonist activity for Regulatory T cells and with an additional amino acid substitution that enable chemical conjugation with Polyethyene Glycol (PEG) that increase circulating half-life compared to the IL-2 selective agonist alone. A preferred IL-2 selective agonist variant is IL2/N88R/C125S/D109C.

Modified IL-2 variants that selectively activate regulatory T cells

The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.

PEGylated aspartyl-tRNA synthetase polypeptides

The present invention provides aspartyl-tRNA synthetase derived proteins (DRS polypeptides) with altered cysteine content, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The DRS polypeptides of the invention have immunomodulatory properties, and exhibit improved activity and stability.

Aspartyl-tRNA synthetases

The present invention relates generally to compositions and methods comprising histidyl-tRNA synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to Jo-1 antibodies.

Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases

This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.

Modified IL-4 mutein receptor antagonists

Growing community of inventors

Branford, CT, United States of America

Jeffrey M Greve